Evidence map›Paper›PMID 36175578›Full record

ArticleMedical oncology (Northwood, London, England)2022

Establishment and characterization of chemotherapy-enriched sphere-forming cells with stemness phenotypes as a new cell line (BAG

Vahid Bagheri, Mehran Gholamin, Atena Mansouri, Mohammad Reza Abbaszadegan

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Vahid BagheriCellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.ORCID http://orcid.org/0000-0002-0114-5370
Mehran GholaminDepartment of Laboratory Sciences, School of Paramedical Sciences, Mashhad University of Medical Sciences, P.O. Box 345-91357, Mashhad, Iran. GholaminM@mums.ac.ir.ORCID http://orcid.org/0000-0002-0123-5755
Atena MansouriCellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.ORCID http://orcid.org/0000-0003-0456-675X
Mohammad Reza AbbaszadeganMedical Genetics Research Center, Mashhad University of Medical Sciences, P.O. Box 345-91357, Mashhad, Iran. abbaszadeganmr@mums.ac.ir.ORCID http://orcid.org/0000-0003-4539-048X
Birjand University of Medical Sciences · IRMashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is a malignancy with a high mortality rate worldwide. Cancer stem cells (CSCs) are a small subpopulation of tumor cells that possess the tumor-initiating ability, self-renewal capacity, and high resistance to conventional therapies. Due to the diversity and complexity of human tumors, new cell lines are urgently needed to supply clinically and physiologically relevant cancer models. Here, we report establishing a novel cell line (BAG

Indexed as

CarcinomaStomach NeoplasmsAnimalsCell LineEpithelial Cell Adhesion MoleculeHumansMiceMice, NudePhenotypeEpithelial Cell Adhesion MoleculeCancer stem cellsGastric cancerNovel cell line

Identifiers

PMID36175578
OpenAlexW4297963694

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.